statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirums LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for LIVMARLI (maralixibat) oral solution for the treatment...

Mirum Pharmaceuticals (MIRM) Gets a Buy from JMP Securities

In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Mirum Pharmaceuticals (MIRM Research Report), with a...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 10, 2024, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock...

Buy Rating Justified: Mirum Pharmaceuticals' Growth Prospects and Market Expansion Post-Livmarli Approval

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Mirum Pharmaceuticals (MIRM Research Report), boosting the price target to...

Buy Rating Affirmed for Mirum Pharmaceuticals on LIVMARLI's EU Approval and Positive Revenue Projections

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Mirum Pharmaceuticals (MIRM Research Report) today and set a price target of $66.00. E...

Mirum Pharmaceuticals LIVMARLI Approved in the European Union for Patients with PFIC

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that the European Commission has granted marketing authorization for LIVMARLI (maralixibat) oral solution for the treatment of progressive...

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the submission of a new drug application (NDA) for chenodiol for the treatment of patients in the U.S. with cerebrotendinous xanthomatosis...

Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies

Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus...

Mirums Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced interim results from two Phase 2b studies evaluating volixibat, an oral ileal bile acid transporter (IBAT) inhibitor in patients with...

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Volume	2.41M
52-Wk High	$41.88
52-Wk Low	$23.14

MIRM Mirum Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals